全球糖尿病眼科治疗市场

到 2030 年，全球糖尿病眼科护理市场规模将达到 461 亿美元

全球糖尿病眼科护理市场规模预计在2024年达到333亿美元，预计在分析期内（2024-2030年）的复合年增长率为5.6%，到2030年将达到461亿美元。糖尿病眼科药物是本报告分析的细分市场之一，预计其复合年增长率为6.6%，到分析期结束时将达到289亿美元。糖尿病眼科设备细分市场在分析期间的复合年增长率预计为4.0%。

美国市场规模估计为 91 亿美元，中国市场预期复合年增长率为 9.0%

美国糖尿病眼科护理市场规模预计在2024年达到91亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到94亿美元，在分析期间（2024-2030年）的复合年增长率为9.0%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为2.6%和5.6%。在欧洲，德国的复合年增长率预计为3.6%。

全球糖尿病眼科护理市场—主要趋势和驱动因素摘要

糖尿病相关的视力丧失如何造成紧急医疗需求？

随着全球糖尿病盛行率的上升，与糖尿病相关的眼部疾病（例如糖尿病视网膜病变、糖尿病黄斑部水肿和青光眼）正受到越来越多的关注。不受控制的血糖值会损害视网膜中脆弱的血管，导致视力逐渐丧失，严重时甚至失明。 2 型糖尿病的盛行率不断上升，尤其是在老化和都市化社会中，这刺激了对高级眼部护理的需求。除了雷射光凝固等传统治疗方法外，还实施了抗血管内皮生长因子 (anti-VEGF) 注射和皮质类固醇植入等更具创新性的治疗方法，并已证明在保护视力方面有更好的效果。光同调断层扫瞄(OCT) 和眼底照相等影像诊断技术的广泛使用，使得更早发现和更有效地管理糖尿病眼科疾病成为可能。此外，随着人们对糖尿病眼部护理的认识不断提高和政府采取的倡议不断增加，更多患者寻求及时治疗，从而推动了市场的发展。

糖尿病患者眼部护理有哪些最新创新？

生物製药、微创手术技术和缓释性给药系统的进步正在改变糖尿病相关眼科疾病的治疗方法。抗VEGF生物製药（例如雷珠单抗和阿柏西普）的引入，透过减少血管渗漏和阻止病情进展，显着改善了糖尿病黄斑部水肿的治疗。此外，基于皮质类固醇的眼内植入也越来越受欢迎，因为它们可以透过更少的注射提供长期缓解，并提高患者的依从性。另一个充满希望的创新领域是基因治疗，旨在透过标靶基因改造恢復正常的视网膜功能。视网膜假体和再生疗法（包括基于干细胞的干预措施）的发展也为重症患者的视力恢復开闢了新的途径。眼科人工智慧 (AI) 的出现进一步优化了治疗途径并改善了临床疗效，尤其是在筛检和早期检测方面。随着製药和医疗设备公司加强研发力度，糖尿病相关眼科护理的未来前景越来越光明。

眼科护理服务的普及将为市场带来哪些好处？

糖尿病眼部护理的主要变化之一是治疗的可及性不断提高，这得益于政府医疗保健倡议、保险覆盖范围的扩大以及远端医疗技术的进步。将基于人工智慧的诊断工具整合到初级保健环境中，可以以及早发现糖尿病视网膜病变，从而减轻专科眼科中心的负担。此外，行动眼科护理单位和社区推广计划在为服务不足的人群提供筛检和治疗服务方面发挥着重要作用。扩大的眼科手术和药物报销政策进一步鼓励更多患者及时接受治疗。在糖尿病盛行率迅速上升的新兴国家，国际合作和官民合作关係正在改善获得先进眼部护理的机会。此外，开发具有成本效益的抗 VEGF 疗法生物相似药有望降低治疗成本，并使尖端疗法更广泛地普及。这种可近性的提高在减少糖尿病患者的可预防失明方面发挥着至关重要的作用。

糖尿病相关眼科护理市场的主要成长动力是什么？

糖尿病相关眼科护理市场的成长受到多种因素的推动，包括全球糖尿病负担的增加、生物製药的日益普及以及早期诊断技术的进步。日益增长的老龄人口患糖尿病眼科疾病的风险很高，这对市场扩张做出了巨大贡献。缓释性植入和基因疗法等药物传递的创新正在提高患者的依从性和临床疗效，进一步推动了对新型疗法的需求。人工智慧在眼科领域的日益普及也提高了早期发现率，并带来了更积极的治疗方法。此外，政府主导的旨在提高眼科护理可及性的宣传计划和政策改革在市场成长中发挥关键作用。远距眼科服务的扩展和行动诊断平台的广泛使用正在缩小医疗保健差距，尤其是在农村和低收入地区。此外，製药公司对眼科研发的投资增加以及生物相似药竞争的兴起，使得先进的治疗方法更加实惠，进一步刺激了市场扩张。在持续的技术创新和患者意识不断提高的推动下，糖尿病相关的眼科护理市场预计将在未来几年持续成长。

部分

类型（糖尿病眼药、糖尿病眼治疗仪）、用途（糖尿病视网膜病变用药、干眼症用药、青光眼用药、眼部过敏/感染疾病用药、其他用药）、最终用途（医院用药、眼科中心用药、门诊中心用药、其他用药）

受访公司范例

• Alcon Management SA
• American Academy of Ophthalmology
• Bausch+Lomb Corp.
• Bausch Health Companies Inc.
• Carl Zeiss Meditec AG
• Eyenuk, Inc.
• F. Hoffmann-La Roche Ltd.
• IRIDEX Corporation
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口情况（成品和原始OEM）预测其竞争地位的变化。这种复杂多变的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Diabetes Associated Ophthalmic Treatment Market to Reach US$46.1 Billion by 2030

The global market for Diabetes Associated Ophthalmic Treatment estimated at US$33.3 Billion in the year 2024, is expected to reach US$46.1 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Diabetic Ophthalmic Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$28.9 Billion by the end of the analysis period. Growth in the Diabetic Ophthalmic Devices segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.1 Billion While China is Forecast to Grow at 9.0% CAGR

The Diabetes Associated Ophthalmic Treatment market in the U.S. is estimated at US$9.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.4 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Diabetes Associated Ophthalmic Treatment Market - Key Trends & Drivers Summarized

How Is Diabetes-Linked Vision Impairment Creating Urgent Medical Needs?

Diabetes-associated ophthalmic conditions, including diabetic retinopathy, diabetic macular edema, and glaucoma, have become a growing concern due to the rising global prevalence of diabetes. Uncontrolled blood sugar levels damage the delicate blood vessels in the retina, leading to progressive vision loss and, in severe cases, blindness. The increasing incidence of type 2 diabetes, particularly in aging populations and urbanizing societies, has fueled the demand for advanced ophthalmic treatments. Conventional treatment approaches, such as laser photocoagulation, are now being supplemented by more innovative therapies, including anti-vascular endothelial growth factor (anti-VEGF) injections and corticosteroid implants, which have demonstrated improved outcomes in preserving vision. The growing accessibility of diagnostic imaging technologies, such as optical coherence tomography (OCT) and fundus photography, is enabling early detection and more effective management of diabetic eye diseases. Furthermore, with increasing awareness and government initiatives focusing on diabetic eye care, more patients are seeking timely treatment, driving the market forward.

What Are the Latest Innovations in Ophthalmic Treatments for Diabetic Patients?

The treatment landscape for diabetes-related eye diseases is undergoing a transformation, with advancements in biologics, minimally invasive surgical techniques, and sustained-release drug delivery systems. The introduction of anti-VEGF biologics, such as ranibizumab and aflibercept, has significantly improved the management of diabetic macular edema by reducing vascular leakage and halting disease progression. Additionally, corticosteroid-based intraocular implants are gaining popularity due to their ability to provide long-term relief with fewer injections, thereby improving patient compliance. Another promising area of innovation is gene therapy, which aims to restore normal retinal function through targeted genetic modifications. The development of retinal prosthetics and regenerative therapies, including stem cell-based interventions, is also opening new avenues for vision restoration in severe cases. The emergence of artificial intelligence (AI) in ophthalmology, particularly in screening and early detection, is further optimizing treatment pathways and improving clinical outcomes. With pharmaceutical and medical device companies intensifying research efforts, the future of diabetes-associated ophthalmic treatment looks increasingly promising.

How Is the Market Benefiting from Increased Accessibility to Eye Care?

One of the major shifts in diabetic eye care is the increased accessibility to treatment, driven by government healthcare initiatives, insurance coverage expansions, and technological advancements in telemedicine. The integration of AI-powered diagnostic tools into primary care settings allows for early identification of diabetic retinopathy, reducing the burden on specialized ophthalmology centers. Additionally, mobile eye care units and community outreach programs are playing a crucial role in bringing screening and treatment services to underserved populations. The expansion of reimbursement policies for ophthalmic procedures and drug therapies is further encouraging more patients to seek timely intervention. In emerging economies, where diabetes prevalence is rising rapidly, international collaborations and public-private partnerships are enhancing access to advanced ophthalmic treatments. Furthermore, the development of cost-effective biosimilars for anti-VEGF therapies is expected to reduce treatment costs, making cutting-edge care more widely available. These improvements in accessibility are playing a pivotal role in curbing preventable blindness among diabetic populations.

What Are the Key Growth Drivers of the Diabetes-Associated Ophthalmic Treatment Market?

The growth in the diabetes-associated ophthalmic treatment market is driven by several factors, including the rising global diabetes burden, increasing adoption of biologic therapies, and advancements in early diagnostic technologies. The growing geriatric population, which is at a higher risk of developing diabetic eye diseases, is significantly contributing to market expansion. Innovations in drug delivery, such as sustained-release implants and gene therapy, are improving patient adherence and clinical efficacy, further boosting demand for novel treatments. The increasing deployment of AI in ophthalmology is also enhancing early detection rates, leading to more proactive treatment approaches. Additionally, government-led awareness programs and policy reforms aimed at improving eye care accessibility are playing a crucial role in market growth. The expansion of teleophthalmology services and the proliferation of mobile diagnostic platforms are bridging healthcare gaps, particularly in rural and low-income regions. Moreover, the growing investments by pharmaceutical companies in ophthalmic R&D and the rise of biosimilar competition are making advanced treatments more affordable, fueling further market expansion. With continuous innovation and increasing patient awareness, the diabetes-associated ophthalmic treatment market is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Diabetes Associated Ophthalmic Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Diabetic Ophthalmic Drugs, Diabetic Ophthalmic Devices); Application (Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy and Infection Application, Other Applications); End-Use (Hospitals End-Use, Ophthalmic Centers End-Use, Ambulatory Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Alcon Management S. A.
• American Academy of Ophthalmology
• Bausch + Lomb Corp.
• Bausch Health Companies Inc.
• Carl Zeiss Meditec AG
• Eyenuk, Inc.
• F. Hoffmann-La Roche Ltd.
• IRIDEX Corporation
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Diabetes Associated Ophthalmic Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Prevalence of Diabetes Throws the Spotlight on Ophthalmic Complications and Treatment Demand
  • Increased Screening and Early Diagnosis Spur Demand for Therapeutics Addressing Diabetic Retinopathy and Macular Edema
  • Growth in Anti-VEGF Therapy Adoption Strengthens the Business Case for Intravitreal Injections and Specialty Drugs
  • Expansion of Retinal Imaging and OCT Technology Enhances Precision in Monitoring Disease Progression
  • Digital Health and AI-Based Diagnostic Tools Accelerate Personalized Care in Diabetic Eye Disease Management
  • Integration of Teleophthalmology in Rural and Underserved Areas Improves Access to Retinal Screenings
  • Growing Use of Combination Therapies and Sustained-Release Implants Enhances Treatment Efficacy and Compliance
  • Reimbursement Policies and National Health Guidelines Drive Uptake of Retinopathy Treatments in Public Healthcare
  • Development of Non-Invasive Delivery Methods and Oral Agents Represents Next Frontier in Treatment Innovation
  • Ongoing Research in Neuroprotective and Anti-Inflammatory Agents Expands the Pipeline Beyond Vascular Targets
  • Patient Education and Awareness Campaigns Support Early Intervention and Regular Eye Exams
  • Rising Geriatric and Type 2 Diabetes Populations Sustain Long-Term Growth in Ophthalmic Interventions
  • Emerging Markets With High Diabetic Burden Offer Substantial Untapped Opportunities for Ophthalmic Drug Expansion
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Diabetes Associated Ophthalmic Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Diabetic Ophthalmic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Diabetic Ophthalmic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Diabetic Ophthalmic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Diabetic Ophthalmic Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Diabetic Ophthalmic Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Diabetic Ophthalmic Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Ambulatory Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Ambulatory Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Ambulatory Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ophthalmic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ophthalmic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Ophthalmic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Diabetic Retinopathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Diabetic Retinopathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Diabetic Retinopathy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Dry Eye Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Dry Eye Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Dry Eye Syndrome Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Glaucoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Glaucoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Glaucoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Eye Allergy & Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Eye Allergy & Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Eye Allergy & Infection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• JAPAN
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• CHINA
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• EUROPE
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• FRANCE
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• GERMANY
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• INDIA
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
• AFRICA
  • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION